Market Currents
The FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The...
-
Friday, February 8, 4:30 PM ETThe FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The approval is based on response rate; as of yet, clinical benefit, such as improvement in survival or symptoms, has not been verified.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
